Spencer Feldman

The addition of atezolizumab to chemoradiation led to meaningful improvements to quality of life for patients with small cell lung cancer.

The 2025 Extraordinary Healer® Award was presented during the 50th Annual Oncology Nursing Society Congress, recognizing oncology nursing professionals' dedication and impact.

Per phase 2 trial data, enhanced dermatologic management showed a reduction in dermatologic AEs in patients with advanced EGFR-mutated NSCLC.

Improved progression-free survival in metastatic urothelial carcinoma was observed in patients experiencing neuropathy, skin rash, and hyperglycemia following enfortumab vedotin.

Neoadjuvant immune checkpoint inhibitors plus chemotherapy also improved efficacy outcomes in PD-L1-positive/ERBB2-negative tumors.

Olaparib after surgery resulted in durable response rates in patients with high-risk biochemically recurrent prostate cancer with BRCA2 alterations.

The use of ruxolitinib presented improved rates of skin/joint responses, cGVHD responses, patient-reports, low NRM, and high FFS in patients with refractory sclerotic cGVHD.

This retrospective, population-based study shows strong efficacy across multiple patient subgroups and different lines of therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Even with a low rates of cardiovascular adverse events in patients treated with immune checkpoint inhibitors, cancer care teams should still focus on multidisciplinary approaches and early recognition of these events.

Adjuvant trastuzumab reveals associations with improved disease-free survival in 1-year vs 9-week administration of the drug in patients with ERBB2-positive breast cancer.

This retrospective review demonstrates the increased use of active surveillance in patients with small nonfunctional pancreatic neuroendocrine tumors.

Oral cannabis extract may be useful as an adjunct for chemotherapy-induced nausea and vomiting, although it may be associated with additional adverse events.

Enzalutamide produces strong indication of improvements in OS, PCS, TTS, and TTR compared with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC).

Compared to sunitinib, nivolumab plus ipilimumab showed increased overall survival and durable response benefits in patients with advanced renal cell carcinoma.

Compared with available literature, the rates of medication-related osteonecrosis of the jaw were higher in patients with breast cancer and bone metastases treated with antiresorptive therapy.

Higher corticosteroid peak dose may worse progression-free and overall survival in several tumor types including melanoma, non-small cell lung cancer, and others.

Increased use of consultations, breast MRIs, genetic counseling, and other testing in high-risk patients were a direct result from nurse-led high risk referral protocols.

A phase 2 study reveals impactful objective response rates with manageable adverse events in patients with relapsed/refractory follicular lymphoma treated with odronextamab.

Advanced practice providers with independent chemotherapy prescribing privileges reported positive responses related to readiness, confidence, and satisfaction.

A behavioral intervention led by oncology nurses alleviated dyspnea in patients with advanced lung cancer, suggesting further research for long-term effects.

Early palliative care improved quality-of-life indicators including coping skills, self-management, and 2-year survival rate in adults with advanced cancer.

The complexity of postoperative delirium in patients with head and neck cancer may require several strategies including pain management and nutritional support, among others.

Olanzapine improved control of nausea and vomiting from moderately emetogenic chemotherapy, which may suggest its use as a standard of care for antiemetic prophylaxis.

Weighted blankets alleviated anxiety for patients with cancer undergoing infusions without interfering with their care.